ITGA2B enhanced differential diagnosis of stage I NSCLC from all controls and from controls with benign pulmonary nodules, compared with SELP or CEA (Figure 5, Table 2, Stage I vs all controls: ITGA2B, AUC = 0.940; SELP, AUC = 0.846; CEA, AUC = 0.694; Stage I vs BPN: ITGA2B, AUC = 0.941; SELP, AUC = 0.833; CEA, AUC = 0.702). This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.